Progress Of Human Epididymis Protein4in Ovarian Carcinoma

Ovarian cancer is the most common malignant tumors of female reproductivesystem, its incidence after cervical cancer and endometrial cancer, but the mortality rateis in the first place. Early ovarian cancer patients often have no obvious clinicalsymptoms, when most of the patients attend doctors’ office with clinical symptomsalways has been in the late stage of disease, poor prognosis. At present, the mainscreening methods such as vaginal ultrasound and serum CA125inspection all havecertain limitations, so people need to look for more reliable tumor markers for earlydiagnosis of ovarian cancer. In recent years, human epididymis protein4(HE4) as anew marker of ovarian cancer has been studied widely at home and abroad, a lot ofresearch has found that: HE4can not only be used in early diagnosis and screening forovarian cancer, but also its level has the correlation with the various clinical pathologicfactors of ovarian cancer, curative effect evaluation, prognosis and recurrence.Thisarticle summarized research progress on serum HE4in ovarian cancer, hoping can givethe clinical work of ovarian cancer more help.